Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Riken Genesis
Tokyo, Tokyo, Japan
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Riken Genesis markets the OncoGuide OncoScreen Plus CDx System, approved for guiding capivasertib treatment in HR-positive, HER2-negative breast cancer, and maintains a diversified portfolio of companion and clinical sequencing diagnostics with growing real-world adoption in Japan.[7][12][18]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Diagnostic reagentIn vitro diagnosticNext-generation sequencingNucleic acid medicineSmall molecule
- Industry
- Molecular Diagnostics
02
Partnerships
Burning Rock BiotechOxford ImmunotecC2i GenomicsAmoy DiagnosticsPREMIA
Beyond the preview
Go deeper on Riken Genesis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Riken Genesis.